Combined inhibition of HSP27 using the antisense oligonucleotide OGX-427 (Apatorsen) and mTOR blockade via Sapanisertib induced a robust synergistic anti-tumor effect across diverse preclinical models, including advanced PC Patient-derived organoid (PDOs) and CRPC xenografts. The gene discussed is MTOR; the disease is neoplasm.